抗利妥昔单抗抗体在原发性膜性肾病患者中的出现情况及临床结局
这项回顾性国际多中心研究纳入74例接受利妥昔单抗治疗的原发性膜性肾病患者,47%的患者在中位9个月后产生抗利妥昔单抗抗体(ARAs)。ARAs与6个月和12个月临床缓解率显著降低、复发率显著升高及B细胞重建率升高相关,且复发出现更早。作者认为ARAs是重要预后因素,对这类患者应考虑奥妥珠单抗或奥法木单抗替代治疗。
要点
- 74例pMN患者中35例(47%)在利妥昔单抗后中位9个月产生ARAs。
- 有ARAs者6个月缓解率31% vs 无ARAs者56%,12个月54% vs 87%。
- 有ARAs者复发率63% vs 29%,复发时间22个月 vs 32个月。
核心结论
- ARAs的出现是pMN最重要的预后因素之一,与利妥昔单抗治疗后缓解率降低和复发率升高显著相关。
研究设计与样本
- 回顾性国际多中心研究,纳入74例接受利妥昔单抗治疗的原发性膜性肾病患者。
主要发现
- 74例中35例(47%)在利妥昔单抗给药后中位9个月(四分位距6-12个月)产生ARAs。
- 第9个月、第12个月及再次给予利妥昔单抗前监测ARA可识别88%的ARA阳性患者。
- 利妥昔单抗后6个月临床缓解率有ARAs组31% vs 无ARAs组56%(P=0.03),12个月有ARAs组54% vs 无ARAs组87%(P=0.0017)。
- 有ARAs组复发率63% vs 无ARAs组29%(P=0.036),6个月B细胞重建率有ARAs组74.2% vs 无ARAs组50%(P=0.048)。
- 有ARAs组复发时间22个月 vs 无ARAs组32个月(P=0.01)。
临床怎么用
- 作者认为对产生ARAs的患者应考虑奥妥珠单抗或奥法木单抗替代治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Rituximab is a first-line treatment for primary membranous nephropathy (pMN), with proven efficacy and safety. The use of monoclonal antibodies such as rituximab can lead to the formation of antidrug antibodies that may interfere with the therapeutic response. In pMN, anti-rituximab antibodies (ARAs) have been shown to neutralize the cytotoxicity of rituximab, thereby increasing the risk of relapse of nephrotic syndrome. However, the kinetics of ARAs over time and the effect of ARA titer on prognosis are unclear. METHODS: This retrospective international multicenter study included 74 patients with pMN treated with rituximab. Here we aimed to clarify the correlation between ARAs and clinical outcome, as well as to evaluate the most appropriate timing of ARA detection. RESULTS: Overall, 35 out of 74 patients (47%) developed ARAs after a median of 9 (interquartile range: 6-12) months following rituximab administration. ARA monitoring at month-9, month-12 and before rituximab readministration identified 88% of patients with ARAs. Clinical remission rate at 6 and 12 months after rituximab administration was significantly lower in patients with ARAs (31% vs. 56%, P = 0.03 and 54% vs. 87%, P = 0.0017, respectively). ARAs were associated with a significantly higher rate of relapse (63% vs. 29%, P = 0.036) and a higher rate of B-cell reconstitution at 6 months (74.2% vs. 50%, P = 0.048). Notably, relapse occurred earlier in patients with ARAs (22 months vs. 32 months, P = 0.01). CONCLUSION: The development of ARAs represents one of the most important prognostic factors in pMN, being significantly associated with a reduced remission rate and a higher relapse rate after rituximab therapy. Alternative therapies with obinutuzumab or ofatumumab should be considered for these patients.
引用
- Allinovi M, Teisseyre M, Accinno M, et al. Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy. Kidney Int Rep. 2025. PMID: 40814630. doi:10.1016/j.ekir.2025.04.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。